Last Updated: 14 Nov 2024
Executive Summary
Biofrontera Inc. (BFRI) is a biopharmaceutical company specializing in developing and supplying dermatological products for treating skin conditions. Despite recent financial challenges, including negative EBITDA and EPS, the company's revenue growth and analyst target price of $11.5 suggest potential for future growth.
Company Overview
Biofrontera is headquartered in Woburn, Massachusetts, and operates in the United States. The company focuses on developing and distributing innovative treatments for various skin conditions, including actinic keratosis, basal cell carcinoma, and psoriasis.
Fundamental Analysis
Financially, Biofrontera has faced challenges, with negative EBITDA and EPS in recent quarters. However, the company's revenue growth of 0.34% year-over-year indicates some positive momentum. Key financial metrics include:
Revenue TTM: $35,241,000
Gross Profit TTM: $13,489,000
Diluted EPS TTM: -$2.38
Return on Assets TTM: -0.402
Return on Equity TTM: -1.494
Technical Analysis
Technically, Biofrontera's stock price has been volatile, trading between a 52-week high of $4.04 and a low of $0.61. The current price of $0.83 is below both the 50-day and 200-day moving averages.
Short Term Outlook
In the short term, Biofrontera faces challenges due to its negative financial performance. However, the company's revenue growth and analyst target price indicate potential for improvement. Investors should monitor the company's upcoming earnings reports and any news regarding product developments or partnerships.
Long Term Outlook
The long-term outlook for Biofrontera depends on its ability to address its financial challenges and execute its growth strategy. If the company can improve its profitability and expand its product portfolio, it may have the potential for significant growth in the future.
Analyst Recommendations
Analysts are generally optimistic about Biofrontera's long-term prospects. One analyst has a Strong Buy rating with a target price of $11.5, while another has a Buy rating. However, investors should note that analyst recommendations can change over time and should not be taken as financial advice.
